利用肠道微生物组对抗驱虫药物耐药性。
Harnessing the gut microbiome in the fight against anthelminthic drug resistance.
机构信息
Department of Microbiology, Oregon State University, Corvallis, OR, 97331, USA; Department of Statistics, Oregon State University, Corvallis, OR, 97331, USA.
Department of Microbiology, Oregon State University, Corvallis, OR, 97331, USA; Department of Biomedical Sciences, Oregon State University, Corvallis, OR, 97331, USA.
出版信息
Curr Opin Microbiol. 2020 Feb;53:26-34. doi: 10.1016/j.mib.2020.01.017. Epub 2020 Feb 28.
Intestinal helminth parasites present major challenges to the welfare of humans and threaten the global food supply. While the discovery of anthelminthic drugs empowered our ability to offset these harms to society, the alarming rise of anthelminthic drug resistance mitigates contemporary efforts to treat and control intestinal helminthic infections. Fortunately, emerging research points to potential opportunities to combat anthelminthic drug resistance by harnessing the gut microbiome as a resource for discovering novel therapeutics and informing responsible drug administration. In this review, we highlight research that demonstrates this potential and provide rationale to support increased investment in efforts to uncover and translationally utilize knowledge about how the gut microbiome mediates intestinal helminthic infection and its outcomes.
肠道寄生虫对人类健康构成重大挑战，并威胁到全球粮食供应。虽然驱虫药物的发现增强了我们抵消这些对社会危害的能力，但驱虫药物耐药性的惊人上升，削弱了我们治疗和控制肠道寄生虫感染的努力。幸运的是，新兴研究为利用肠道微生物组作为发现新疗法的资源并为负责任的药物管理提供信息，提供了对抗驱虫药物耐药性的潜在机会。在这篇综述中，我们强调了展示这种潜力的研究，并提供了支持增加投资以揭示和转化利用关于肠道微生物组如何介导肠道寄生虫感染及其结果的知识的理由。
Zotero 插件